Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service BPH procedures cases in New Mexico: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 17 | 1,430 | 40% |
| 2020 | 14 | 1,025 | 43% |
| 2021 | 11 | 1,015 | 46% |
| 2022 | 16 | 889 | 50% |
| 2023 | 9 | 511 | 53% |
| 2024 | 10 | 453 | 54% |
| 2025 from claims | – | 401 324–471 | 54% |
| 2026 forecast | – | 400 313–503 | 55% |
| 2027 forecast | – | 403 299–532 | 55% |
| 2028 forecast | – | 405 287–559 | 56% |
| 2029 forecast | – | 408 277–584 | 56% |
| 2030 forecast | – | 410 269–609 | 56% |
TURP, laser enucleation and vaporization, UroLift, Rezum. Professional codes (what the surgeon bills): CPT 52601, 52648, 52649, 52441, 52442, 53854, 55874.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Mexico; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 3% inpatient hospital, 90% hospital outpatient, 7% office. The share outside the hospital has moved −22 pts since 2019.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~400 | ~12 | ~370 | ~21 |
| 2027 · ~400 | ~13 | ~370 | ~18 |
| 2028 · ~410 | ~13 | ~370 | ~17 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: office about 4% (7% in 2025), hospital outpatient about 92% (90% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 202 | 14,148−8%/yr | −8%/yr | 4.2 | 48% | 14,100 in 2030−0.1%/yr |
| Arizona | 79 | 6,117−8.2%/yr | −8.2%/yr | 8.2 | 55% | 6,220 in 2030+0.3%/yr |
| Washington | 49 | 3,507−5.1%/yr | −5.1%/yr | 4.5 | 27% | 3,370 in 2030−0.6%/yr |
| Colorado | 49 | 2,851−4%/yr | −4%/yr | 5.8 | 43% | 2,530 in 2030−2%/yr |
| Oregon | 25 | 1,987−8.3%/yr | −8.3%/yr | 4.7 | 44% | 1,720 in 2030−2.4%/yr |
| Utah | 29 | 1,113−15%/yr | −15%/yr | 5.1 | 14% | 1,080 in 2030−0.5%/yr |
| Idaho | 17 | 1,020−1.6%/yr | −1.6%/yr | 5.0 | 38% | 1,180 in 2030+2.4%/yr |
| Nevada | 22 | 901−13%/yr | −13%/yr | 3.1 | 60% | 1,050 in 2030+2.5%/yr |
| Montana | 12 | 679−16%/yr | −16%/yr | 3.6 | 7% | 580 in 2030−2.5%/yr |
| Alaska | 6 | 477+20%/yr | +20%/yr | 4.0 | 59% | 640 in 2030+5%/yr |
| Hawaii | 5 | 293−11%/yr | −11%/yr | 2.3 | 43% | 390 in 2030+5%/yr |
| Wyoming | 4 | 186−7.9%/yr | −7.9%/yr | 1.7 | 39% | 240 in 2030+4.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 11 | 549−4.5%/yr | −4.5%/yr | 2.40.7× | 2% | 570 in 2030+0.7%/yr |
| Hysterectomy, hysteroscopy & ablation | 5 | 427−0.8%/yr | −0.8%/yr | 2.00.9× | 16% | 400 in 2030−1.2%/yr |
| Incontinence, prolapse & sacral neuromodulation | 2 | 167−7.1%/yr | −7.1%/yr | 0.70.4× | 9% | 240 in 2030+6.5%/yr |
BPH procedures in every state, and its device makers · Every procedure market in New Mexico · Every state · Compare with California
Olympus leads with 97% of company spending on these surgeons in 2025, +10 pts on 2024.
In 2025, 5 companies reported engagement with New Mexico’s surgeons worth $25K in consulting, speaking, meals and travel tied to these products, about $2,506 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.